In clinical use, protease inhibitors need to be used together with other anti AIDS drugs, namely the so-called cocktail therapy. Protease inhibitors include ritonavir, indinavir, azanavir, darunavir, etc.
1. Litonavir: Oral absorption is good, and animal experiments have shown that its bioavailability is about 60% to 80%. Food can affect its absorption. The distribution volume is about 0.4L/kg, and the protein binding rate is 98%~99%. It is mainly metabolized by the liver, and its main metabolites have antiviral activity;
2. Indinavir: This product can prevent many viral proteins from breaking down into functional proteins, forming non infectious viral particles. Has antiviral activity against HIV, including laboratory virus strains and clinical isolates (including strains resistant to nucleoside and non nucleoside HIV reverse transcriptase inhibitors);
3. Azanavir: This product is a nitrogen-containing peptide HIV-1 protease inhibitor. The mechanism of action is to selectively inhibit the specific processing of virus Gag and Gag pol polymeric proteins in HIV-1 infected cells, thereby blocking the formation of mature viruses;
4. Darunavir:selectively inhibits the division of the precursor protein encoding Gag Pol in infected cells, thereby inhibiting the formation of mature viral particles. Darunavir interacts with the protease of HIV, and for treated patients with multidrug-resistant mutations in protease inhibitors, Darunavir may still exert effective antiviral effects.
